Difference to be detected | Difference to be detected expressed as odds ratio | |||
---|---|---|---|---|
Factors tested | Mean reduction in death or cancer recurrence^{a}, % (95 % CI) | P-value | Mean odds ratio (95 % CI) | P-value |
Baseline risk | <0.001 | 0.930 | ||
Low risk (10 % of mortality/recurrence) (n = 183) High risk (60 % of mortality/recurrence) (n = 170) |
3.2 (2.4–4.0) 11.2 (10.3–12.0) | 0.230 |
0.64 (0.61–0.67) 0.63 (0.60–0.66) | |
Primary outcome | 0.322 | |||
Mortality (n = 174) Recurrence rate (n = 179) |
6.7 (5.9–7.5) 7.4 (6.6–8.2) | 0.649 |
0.65 (0.62–0.68) 0.62 (0.60–0.65) | |
Disadvantages of the new treatment | 0.206 | |||
Higher cost mentioned (n = 180) Higher cost not mentioned (n = 173) |
7.2 (6.4–8.0) 6.9 (6.1–7.7) | 0.005 |
0.62 (0.59–0.65) 0.65 (0.62–0.68) | |
Study population | 0.031 | |||
Adults aged <50 years (n = 180) Adults aged >75 years (n = 173) |
7.9 (7.1–8.7) 6.2 (5.4–7.0) |
0.61 (0.59–0.64) 0.66 (0.63–0.69) |